Please use this identifier to cite or link to this item:
|Title:||Single-agent irinotecan as second-line treatment for advanced gastric cancer|
|Authors:||Uludağ Üniversitesi/Tıp Fakültesi/Medikal Onkoloji Anabilim Dalı.|
Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.
|Citation:||Kanat, O. vd. (2003). “Single-agent irinotecan as second-line treatment for advanced gastric cancer”. Tumori Journal, 89(4), 405-407.|
|Abstract:||Aim. To investigate the activity and toxicity of irinotecan (CPT-11) as a single agent in patients with advanced gastric cancer after failure of previous 5-fluorouracil-based combination chemotherapy. Patients and methods: Sixteen patients with advanced gastric received CPT-11, 350 mg/m2 every 21 days. The median age of the patients was 54.6 years; ECOG performance status was 0-1 in 14 patients and 2 in 2 patients. Dominant metastatic sites included liver, lung, lymph nodes and peritoneum. Results: No complete response was observed. Two patients (12.5%) achieved a partial response to treatment. One patient (6.25%) had a minor response. Ten patients (62.5%) had progressive disease on therapy, and 3 patients (18.75%) had stable disease. The median survival of all 16 patients was 5 months. Grade 3 neutropenia was observed in 3 patients (18.75%), grade 4 thrombocytopenia in 1 patient (6.25%), and grade 3 anemia in 1 patient (6.25%). Three patients (18.75%) suffered from grade 3 diarrhea. Conclusions: CPT-11 is moderately active and a well-tolerated regimen for selected advanced gastric cancer patients who experience disease progression after receiving first-line treatment.|
|Appears in Collections:||Scopus|
Web of Science
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.